Prospective study of a web-mediated management of febrile neutropenia related to chemotherapy (Bioconnect)

  • Fabrice DenisEmail author
  • Eric Voog
  • Yoann Pointreau
  • Hugues Bourgeois
  • Valérie Seegers
  • Katell Le Du
Original Article



We aimed to investigate whether patient self-evaluated symptoms transmitted via Internet is feasible between planned visits to provide an early management of fever and neutropenia induced by chemotherapy, and if it can reduce hospitalizations for severe neutropenia.


Patients who received a chemotherapy regimen with an overall risk of febrile neutropenia ≥ 20% had to report daily temperature between physician planned visits using a web application. Fever and clinical signs of seriousness were reported to the physician (if some criteria were fulfilled in a specific algorithm) via automatic email notifications by the web application. Patients could be hospitalized quickly or could take over at home, make blood count, and take predefined oral antibiotics if indicated. Primary outcome was patient’s compliance and satisfaction. The number and the cost of hospitalization were also assessed and compared with an historical cohort of patients with similar clinical conditions and treatment.


Among the 41 patients included, 36 (87.8%) used the web application with 88% of daily compliance and 90% (28/33) of satisfaction. One patient (2.7%) had planned hospitalization after the web application alert. In the historical cohort, the rate of unplanned hospitalization for febrile neutropenia was 17% (6 patients) and 2.7% (1 patient) in users of the web application cohort. The cumulative cost of hospitalization for neutropenia was USD 28,827 in the historical cohort and USD 6563 in the web application cohort.


Web-mediated follow-up of febrile neutropenia is feasible. It led to high patient satisfaction, high compliance, and a possible reduction of the number and the cost of hospitalizations.


e-health Neutropenia Chemotherapy Clinical trial 



We thank the patients and their families for their participation in this study, as well as investigators, promotor: Integrated Center for Oncology (ICO, Angers, France), Anne-Lise Septans for statistical analysis, Magali Balavoine for trial monitoring, and sponsors: CHUGAI PHARMA France and SIVAN Innovation Ltd. for financial sponsorship.


This work was supported by CHUGAI PHARMA France and SIVAN Innovation Ltd.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.


  1. 1.
    Selby JV, Beal AC, Frank L (2012) The Patient-Centered Outcomes Research Institute (PCORI) national priorities for research and initial research agenda. JAMA 307:1583–1584CrossRefPubMedGoogle Scholar
  2. 2.
    Basch E, Artz D, Dulko D, Scher K, Sabbatini P, Hensley M, Mitra N, Speakman J, McCabe M, Schrag D (2005) Patient online self-reporting of toxicity symptoms during chemotherapy. J Clin Oncol 23:3552–3561CrossRefPubMedGoogle Scholar
  3. 3.
    Bakitas MA, Tosteson TD, Li Z, Lyons KD, Hull JG, Li Z, Dionne-Odom JN, Frost J, Dragnev KH, Hegel MT, Azuero A, Ahles TA (2015) Early versus delayed initiation of concurrent palliative oncology care: patient outcomes in the ENABLE III randomized controlled trial. J Clin Oncol 33:1438–1445CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Basch E, Deal AM, Kris MG et al (2015) Symptom monitoring with patient-reported outcomes during routine cancer treatment: a randomized controlled trial. J Clin Oncol 34:557–565CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Denis F, Viger L, Charron A, Voog E, Letellier C (2014) Detecting lung cancer relapse using self-evaluation forms weekly filled at home: the sentinel follow-up. Support Care Cancer 22:79–85CrossRefPubMedGoogle Scholar
  6. 6.
    Denis F, Viger L, Charron A, Voog E, Dupuis O, Pointreau Y, Letellier C (2014) Detection of lung cancer relapse using self-reported symptoms transmitted via an Internet web-application: pilot study of the sentinel follow-up. Support Care Cancer 22:1467–1473CrossRefPubMedGoogle Scholar
  7. 7.
    Denis F, Yossi S, Septans AL et al (2015) Improving survival in patient treated for a lung cancer using self-evaluated symptoms reported via a web-application. Am J Clin OncolGoogle Scholar
  8. 8.
    Denis F, Lethrosne C, Pourel N, Molinier O, Pointreau Y, Domont J, Bourgeois H, Senellart H, Trémolières P, Lizée T, Bennouna J, Urban T, el Khouri C, Charron A, Septans AL, Balavoine M, Landry S, Solal-Céligny P, Letellier C (2017) Randomized trial comparing a web-mediated follow-up to routine surveillance in lung cancer patients. J Natl Cancer Inst 109(9).
  9. 9.
    Kuderer NM, Dale DC, Crawford J, Cosler LE, Lyman GH (2006) Mortality, morbidity and cost associated with febrile neutropenia in adult cancer patients. Cancer 106(10):2258–2266CrossRefPubMedGoogle Scholar
  10. 10.
    Freifeld AG, Bow EJ, Sepkowitz KA, Boeckh MJ, Ito JI, Mullen CA, Raad II, Rolston KV, Young JA, Wingard JR, Infectious Diseases Society of America (2011) Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of America. Clin Infect Dis 52(4):e56–e93CrossRefPubMedGoogle Scholar
  11. 11.
    Kuderer NM, Dale DC, Crawford J, Lyman GH (2007) Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review. J Clin Oncol 25(21):3158–3167CrossRefPubMedGoogle Scholar
  12. 12.
    Freyer G, Scotte F, Borget I, Bruyas A, Vainchtock A, Chouaid C (2016) Hospitalisations pour neutropénie fébrile chimio-induite en France en 2010–2011: impact clinique et caractéristiques des patients à partir des données de la base PMSI. Bull Cancer 103:552–560CrossRefPubMedGoogle Scholar
  13. 13.
    Tai E, Guy GP, Dunbar A, Richardson LC (2017) Cost of cancer-related neutropenia or fever hospitalizations, United States, 2012. J Oncol Pract.
  14. 14.
    (2012) National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology (NCCN Guidelines®). Myeloid growth factors. v1Google Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Institut Inter-régional de Cancérologie Jean BernardLe MansFrance
  2. 2.CORIA UMR 6614—Normandie UniversitéCNRS – Université et INSA de RouenSaint-Étienne-du-RouvrayFrance
  3. 3.Institut de Cancérologie de l’Ouest Paul PapinAngersFrance

Personalised recommendations